Literature DB >> 24099838

Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion.

Christine H Kim1, Fady Khoury-Collado, Emma L Barber, Robert A Soslow, Vicky Makker, Mario M Leitao, Yukio Sonoda, Kaled M Alektiar, Richard R Barakat, Nadeem R Abu-Rustum.   

Abstract

OBJECTIVE: To report the incidence of nodal metastases in patients presenting with presumed low-grade endometrioid adenocarcinomas using a sentinel lymph node (SLN) mapping protocol including pathologic ultrastaging.
METHODS: All patients from 9/2005 to 12/2011 who underwent endometrial cancer staging surgery with attempted SLN mapping for preoperative grade 1 (G1) or grade 2 (G2) tumors with <50% invasion on final pathology, were included. All lymph nodes were examined with hematoxylin and eosin (H&E). Negative SLNs were further examined using an ultrastaging protocol to detect micrometastases and isolated tumor cells.
RESULTS: Of 425 patients, lymph node metastasis was found in 25 patients (5.9%) on final pathology-13 cases on routine H&E, 12 cases after ultrastaging. Patients whose tumors had a DMI <50% were more likely to have positive SLNs on routine H&E (p<0.005) or after ultrastaging (p=0.01) compared to those without myoinvasion.
CONCLUSIONS: Applying a standardized SLN mapping algorithm with ultrastaging allows for the detection of nodal disease in a presumably low-risk group of patients who in some practices may not undergo any nodal evaluation. Ultrastaging of SLNs can likely be eliminated in endometrioid adenocarcinoma with no myoinvasion. The long-term clinical significance of ultrastage-detected nodal disease requires further investigation as recurrences were noted in some of these cases.
© 2013.

Entities:  

Keywords:  Endometrial cancer staging; Isolated tumor cells; Low-grade endometrioid carcinoma; Micrometastasis; Sentinel lymph node mapping; Ultrastaging

Mesh:

Year:  2013        PMID: 24099838      PMCID: PMC3881432          DOI: 10.1016/j.ygyno.2013.09.027

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  29 in total

1.  Predictors of final histology in patients with endometrial cancer.

Authors:  Michael Frumovitz; Diljeet K Singh; Larissa Meyer; Daniel H Smith; Iris Wertheim; Ephraim Resnik; Diane C Bodurka
Journal:  Gynecol Oncol       Date:  2004-12       Impact factor: 5.482

2.  The prognostic significance of surgical staging for carcinoma of the endometrium.

Authors:  A H Wolfson; S E Sightler; A M Markoe; J G Schwade; H E Averette; P Ganjei; S G Hilsenbeck
Journal:  Gynecol Oncol       Date:  1992-05       Impact factor: 5.482

3.  The ability to evaluate prognostic variables on frozen section in hysterectomies performed for endometrial carcinoma.

Authors:  J S Noumoff; A Menzin; J Mikuta; E J Lusk; M Morgan; V A LiVolsi
Journal:  Gynecol Oncol       Date:  1991-09       Impact factor: 5.482

4.  Accuracy of office and operating room curettage in the grading of endometrial carcinoma.

Authors:  A G Daniel; W A Peters
Journal:  Obstet Gynecol       Date:  1988-04       Impact factor: 7.661

5.  Accuracy of intraoperative frozen-section diagnosis in stage I endometrial adenocarcinoma.

Authors:  E Kucera; C Kainz; A Reinthaller; G Sliutz; S Leodolter; H Kucera; G Breitenecker
Journal:  Gynecol Obstet Invest       Date:  2000       Impact factor: 2.031

6.  Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.

Authors:  W T Creasman; C P Morrow; B N Bundy; H D Homesley; J E Graham; P B Heller
Journal:  Cancer       Date:  1987-10-15       Impact factor: 6.860

7.  Risk factors and recurrent patterns in Stage I endometrial cancer.

Authors:  P J DiSaia; W T Creasman; R C Boronow; J A Blessing
Journal:  Am J Obstet Gynecol       Date:  1985-04-15       Impact factor: 8.661

8.  Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence.

Authors:  K M Greven; R M Lanciano; B Corn; D Case; M E Randall
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

9.  Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging.

Authors:  Christine H Kim; Robert A Soslow; Kay J Park; Emma L Barber; Fady Khoury-Collado; Joyce N Barlin; Yukio Sonoda; Martee L Hensley; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Int J Gynecol Cancer       Date:  2013-06       Impact factor: 3.437

10.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.

Authors:  Henry M Keys; James A Roberts; Virginia L Brunetto; Richard J Zaino; Nick M Spirtos; Jeffrey D Bloss; Andrew Pearlman; Mitchell A Maiman; Jeffrey G Bell
Journal:  Gynecol Oncol       Date:  2004-03       Impact factor: 5.482

View more
  11 in total

Review 1.  Current status of molecular biomarkers in endometrial cancer.

Authors:  H M J Werner; H B Salvesen
Journal:  Curr Oncol Rep       Date:  2014-09       Impact factor: 5.075

2.  Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More.

Authors:  Mario M Leitao
Journal:  Curr Obstet Gynecol Rep       Date:  2016-10-03

3.  Sentinel Lymph Node Mapping in Endometrial Cancer: An Update.

Authors:  Fady Khoury-Collado; Caryn St Clair; Nadeem R Abu-Rustum
Journal:  Oncologist       Date:  2016-03-09

4.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

5.  Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.

Authors:  Jennifer J Mueller; Silvana Pedra Nobre; Kenya Braxton; Kaled M Alektiar; Mario M Leitao; Carol Aghajanian; Lora H Ellenson; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2020-04-01       Impact factor: 5.482

6.  Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models.

Authors:  Bingyi Yang; Boer Shan; Xiaohong Xue; Huaying Wang; Weiwei Shan; Chengcheng Ning; Qiongjie Zhou; Xiaojun Chen; Xuezhen Luo
Journal:  PLoS One       Date:  2016-05-10       Impact factor: 3.240

7.  Sentinel-lymph-node mapping with indocyanine green in robotic-assisted laparoscopic surgery for early endometrial cancer: a retrospective analysis.

Authors:  V Cela; C Sergiampietri; M E Rosa Obino; G Bifulco; P Giovanni Artini; F Papini
Journal:  Facts Views Vis Obgyn       Date:  2020-03-27

Review 8.  The Perspectives of Fertility Preservation in Women with Endometrial Cancer.

Authors:  Jure Knez; Leyla Al Mahdawi; Iztok Takač; Monika Sobočan
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

9.  Retroperitoneal Sentinel Lymph Node Biopsy by Vaginally Assisted Natural Orifices Endoscopic Transluminal Endoscopic Surgery in Early Stage Endometrial Cancer: Description of Technique and Surgeon's Perspectives after the First Experience.

Authors:  Marie-Pierre Mathey; Fabien Romito; Daniela E Huber
Journal:  Case Rep Oncol       Date:  2022-03-21

10.  Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer.

Authors:  Hans Nagar; Nina Wietek; Richard J Goodall; Will Hughes; Mia Schmidt-Hansen; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.